Live
- PM Modi highlights govt's efforts to make Odisha prosperous and one of the fastest-growing states
- Hezbollah fires 200 rockets at northern, central Israel, injuring eight
- Allu Arjun's Family Appearance on Unstoppable with NBK Breaks Viewership Records
- Unity of hearts & minds essential for peace & progress, says J&K Lt Governor
- IPL 2025 Auction: I deserve Rs 18 cr price, says Chahal on being acquired by Punjab Kings
- EAM Jaishankar inaugurates new premises of Indian embassy in Rome
- Sailing vessel INSV Tarini embarks on second leg of expedition to New Zealand
- Over 15,000 people affected by rain-related disasters in Sri Lanka
- IPL 2025 Auction: RCB acquire Hazlewood for Rs 12.50 cr; Gujarat Titans bag Prasidh Krishna at Rs 9.5 crore
- Maharashtra result reflects the outcome of Congress' destructive politics: BJP's Shazia Ilmi
Indian Covid-19 Vaccine Is Effective And Has No Safety Issues
Tamil Nadu inoculates 8.36 lakh people in 9th mega vaccination drive
- Bharat Biotech's Covid-19 vaccine is 'very effective' and poses no safety risks.
- A detailed experiment enrolling 24,419 individuals aged 18-97 years in India between November 2020 and May 2021 found no serious vaccine-related deaths or serious incidents
On Thursday, according to a recent study published in the medical journal The Lancet, Bharat Biotech's Covid-19 vaccine is 'very effective' and poses no safety risks. The Lancet reported that Bharat Biotech's Covaxin had a 77.8% effectiveness rate among symptomatic Covid-19 patients. The Lancet noted in a statement that covaxin stimulates a significant antibody response within two weeks following two doses are provided. A detailed experiment enrolling 24,419 individuals aged 18-97 years in India between November 2020 and May 2021 found no serious vaccine-related deaths or serious incidents, according to the medical publication. Bharat Biotech and the Indian Council of Medical Research jointly sponsored the interim study, which was co-authored by staff from both organisations.
The World Health Organization has granted Covaxin emergency clearance, and it is now approved for use in 17 nations. Covaxin has been added to the WHO-approved list of anti-Covid vaccinations produced by Pfizer/BioNTech, Moderna, AstraZeneca, Johnson&Johnson, Sinopharm, and Sinovac, reported LiveMint.
According to the UN organisation, it is particularly ideal for low- and middle-income nations due to simple preservation needs. However, further studies is needed to determine Covaxin's long-term safeness and efficacy, as well as its capacity to guard from hospitalisation, death, and the Covid delta variant and additional variants of concern.
